Protective effect of naturally occurring anti-HER2 autoantibodies on breast cancer

Breast Cancer Research and Treatment

Volumn 157, Issue 1, 2016, Pages 55-63

  Tabuchi, Yukiko ^a   Shimoda, Masafumi ^a   Kagara, Naofumi ^a   Naoi, Yasuto ^a   Tanei, Tomonori ^a   Shimomura, Atsushi ^a   Shimazu, Kenzo ^a   Kim, Seung Jin ^a   Noguchi, Shinzaburo ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Autoantibodies; Enzyme linked immunosorbent assay; HER2; Humoral immunity; Immunotherapy

Indexed keywords

AUTOANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 AUTOANTIBODY; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER RISK; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; TUMOR IMMUNITY; BLOOD; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DISEASE FREE SURVIVAL; IMMUNOLOGY; MIDDLE AGED; ODDS RATIO; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; ODDS RATIO; RECEPTOR, ERBB-2;

EID: 84964465652     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-016-3801-4     Document Type: Article

References (29)

1. Parmiani G, De Filippo A, Novellino L, Castelli C (2007) Unique human tumor antigens: immunobiology and use in clinical trials. J Immunol 178:1975–1979
2. Finn O (2008) Cancer immunology. N Engl J Med 358:2704–2715
3. Lu H, Goodell V, Disis ML (2008) Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res 7:1388–1394
4. Chapman C, Murray A, Chakrabarti J et al (2007) Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol 18:868–873
5. Graus F, Dalmou J, Rene R et al (1997) Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol 15:2866–2872
6. Patton S, Gendler SJ, Spicer AP (1995) The epithelial mucin, MUC1, of milk, mammary gland and other tissues. Biochim Biophys Acta 1241:407–423
7. Taylor-Papadimitriou J, Burchell JM, Plunkett T et al (2002) MUC1 and the immunobiology of cancer. J Mammary Gland Biol Neoplasia 7:209–221
8. von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P et al (2000) Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 18:574–583
9. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ (2011) Natural innate and adaptive immunity to cancer. Ann Rev Immunol 29:235–271
10. DiLillo DJ, Yanaba K, Tedder TF (2010) B cells are required for optimal CD4 + and CD8 + T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol 184:4006–4016
11. Li Q, Lao X, Pan Q et al (2011) Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. Clin Cancer Res 17:4987–4995
12. Carmi Y, Spitzer MH, Linde IL et al (2015) Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity. Nature 521:99–104
13. Hudis CA (2007) Trastuzumab—mechanism of action and use in clinical practice. N Engl J Med 357:39–51
14. Disis ML, Pupa SM, Gralow JR et al (1997) High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 15:3363–3367
15. Lauterlein JJL, Petersen ER, Olsen DA et al (2011) Quantification of HER2 autoantibodies in the amplification phenomenon of HER2 in breast cancer. Clin Chem Lab Med 49:877–883
16. Goldhirsch A, Wood WC, Gelber RD et al (2003) Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21:3357–3365
17. Goldhirsch A, Glick JH, Gelber RD et al (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569–1583
18. Goldhirsch A, Wood WC, Gelber RD et al (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18:1133–1144
19. Goldhirsch A, Ingle JN, Gelber RD et al (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20:1319–1329
20. Morimoto K, Kim SJ, Tanei T et al (2009) Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci 100:1062–1068
21. Goodell V, Disis ML (2005) Human tumor cell lysates as a protein source for the detection of cancer antigen-specific humoral immunity. J Immunol Methods 299:129–138
22. Montgomery RB, Makary E, Schiffman K et al (2005) Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase. Cancer Res 65:650–656
23. Gianni L, Eiermann W, Semiglazov V et al (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375:377–384
24. Paik S, Kim C, Wolmark N (2008) HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 358:1409–1411
25. Perez EA, Reinholz MM, Hillman DW et al (2010) HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol 28:4307–4315
26. Ithimakin S, Day KC, Malik F et al (2013) HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res 73:1635–1646
27. Pogue-Geile KL, Kim C, Jeong JH et al (2013) Predicting degree of benefit from adjuvant trastuzumab in NSABP Trial B-31. J Natl Cancer Inst 105:1782–1788
28. Milani A, Sangiolo D, Aglietta M, Valabrega G (2014) Recent advances in the development of breast cancer vaccines. Breast Cancer 6:159–168
29. Mittendorf EA, Clifton GT, Holmes JP et al (2014) Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann Oncol 25:1735–1742